Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs TransMedics Group Inc (TMDX) Price & Performance

State Street SPDR Bloomberg High Yield Bond ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg High Yield Bond ETF vs TransMedics Group Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.75, while TransMedics Group Inc trades at $86.75 (market cap $3.10B). Which is the better fit depends on your goals.

JNKTMDX
Sector
Fixed IncomeTechnology
52-Week High
$98.19$150.42
52-Week Low
$94.66$61.99
Market Cap
$3.10B
Enterprise Value
$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg High Yield Bond ETF

JNK trades at $95.85, up 0.21% with a bearish technical signal from moving averages and oscillators neutral. Recent news highlights bond market volatility amid inflation data and Middle East tensions, with Fitch Ratings warning of AI-related corporate credit risks. The ETF maintains dividend distributions, with recent payouts around $0.52-$0.53.

Outlook is cautious due to macroeconomic headwinds and credit risks, but higher yields may attract income investors. Key risks include Fed policy uncertainty and oil price fluctuations impacting bond markets. Analyst sentiment is mixed, balancing yield appeal against fee concerns and market volatility.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg High Yield Bond ETF

JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.

Read more on JNK

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX